Cargando…

All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease

AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model o...

Descripción completa

Detalles Bibliográficos
Autores principales: Copetti, Massimiliano, Biancalana, Edoardo, Fontana, Andrea, Parolini, Federico, Garofolo, Monia, Lamacchia, Olga, De Cosmo, Salvatore, Trischitta, Vincenzo, Solini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164049/
https://www.ncbi.nlm.nih.gov/pubmed/34050821
http://dx.doi.org/10.1007/s00592-021-01746-2
Descripción
Sumario:AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up. RESULTS: ENFORCE’s survival C-statistic was 0.81 (95%CI: 0.72–0.89) and 0.78 (95%CI: 0.68–0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes. CONCLUSIONS: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-021-01746-2.